|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
IL166241A0
(en)
|
2002-07-29 |
2006-01-15 |
Rigel Pharmaceuticals Inc |
Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
|
|
US8178671B2
(en)
|
2003-07-30 |
2012-05-15 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
|
|
AU2011253635B2
(en)
*
|
2003-09-17 |
2014-10-30 |
Janssen Pharmaceutica, N.V. |
Fused heterocyclic compounds
|
|
WO2005040169A2
(en)
*
|
2003-09-17 |
2005-05-06 |
Janssen Pharmaceutica, N.V. |
Fused heterocyclic compounds as serotonin receptor modulators
|
|
US7473783B2
(en)
|
2003-12-17 |
2009-01-06 |
Sgx Pharmaceuticals, Inc. |
Bicyclic pyrazolo protein kinase modulators
|
|
WO2005123111A2
(en)
*
|
2004-06-21 |
2005-12-29 |
Exelixis, Inc. |
Maxs as modifiers of the axin pathway and methods of use
|
|
CA2581454A1
(en)
|
2004-09-23 |
2006-03-30 |
Reddy Us Therapeutics, Inc. |
Novel pyrimidine compounds, process for their preparation and compositions containing them
|
|
EP1856135B1
(en)
|
2005-01-19 |
2009-12-09 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
CN105348203B
(zh)
|
2005-06-08 |
2018-09-18 |
里格尔药品股份有限公司 |
抑制jak途径的组合物和方法
|
|
US8962643B2
(en)
*
|
2006-02-24 |
2015-02-24 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
|
CA2650140A1
(en)
*
|
2006-04-14 |
2007-10-25 |
Mriganka Sur |
Identifying and modulating molecular pathways that mediate nervous system plasticity
|
|
EP2044056B1
(en)
*
|
2006-07-14 |
2012-08-22 |
Novartis AG |
Pyrimidine derivatives as alk-5 inhibitors
|
|
CA2668159A1
(en)
*
|
2006-11-01 |
2008-07-03 |
Vertex Pharmaceuticals Incorporated |
Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
|
|
US20100137398A1
(en)
*
|
2007-05-04 |
2010-06-03 |
Novartis Ag |
Use of hdac inhibitors for the treatment of gastrointestinal cancers
|
|
LT2265607T
(lt)
*
|
2008-02-15 |
2017-03-27 |
Rigel Pharmaceuticals, Inc. |
Pirimidin-2-amino junginiai ir jų panaudojimas kaip jak kinazių slopiklių
|
|
US8063058B2
(en)
|
2008-04-16 |
2011-11-22 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk and JAK protein kinases
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
WO2009131687A2
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
JP5063815B2
(ja)
*
|
2008-11-25 |
2012-10-31 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
|
|
WO2010093808A1
(en)
*
|
2009-02-11 |
2010-08-19 |
Reaction Biology Corp. |
Selective kinase inhibitors
|
|
US8663210B2
(en)
|
2009-05-13 |
2014-03-04 |
Novian Health, Inc. |
Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
|
|
JO3030B1
(ar)
*
|
2009-06-26 |
2016-09-05 |
Galapagos Nv |
مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
|
|
WO2011008915A1
(en)
*
|
2009-07-15 |
2011-01-20 |
Abbott Laboratories |
Pyrrolopyridine inhibitors of kinases
|
|
WO2011017178A1
(en)
*
|
2009-07-28 |
2011-02-10 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2011025947A1
(en)
*
|
2009-08-28 |
2011-03-03 |
Array Biopharma Inc. |
Raf inhibitor compounds and methods of use thereof
|
|
UY33213A
(es)
*
|
2010-02-18 |
2011-09-30 |
Almirall Sa |
Derivados de pirazol como inhibidores de jak
|
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
|
JP6039683B2
(ja)
|
2011-11-23 |
2016-12-07 |
ポートラ ファーマシューティカルズ， インコーポレイテッド |
ピラジンキナーゼ阻害剤
|
|
WO2013113762A1
(en)
|
2012-01-31 |
2013-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
|
|
CN104334191A
(zh)
*
|
2012-03-29 |
2015-02-04 |
纽约市哥伦比亚大学托管会 |
治疗毛发脱落疾病的方法
|
|
SMT201800608T1
(it)
|
2012-04-24 |
2019-01-11 |
Vertex Pharma |
Inibitori di dna-pk
|
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
|
EP2903970A4
(en)
|
2012-10-08 |
2016-11-30 |
Portola Pharm Inc |
SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
|
|
AU2014244555B2
(en)
|
2013-03-12 |
2018-06-28 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
|
HUE041877T2
(hu)
|
2013-10-17 |
2019-06-28 |
Vertex Pharma |
(S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként
|
|
DK3126352T3
(en)
*
|
2014-04-04 |
2019-01-21 |
Syros Pharmaceuticals Inc |
CYCLINE INDEPENDENT KINASE 7 INHIBITORS (CDK7)
|
|
US9550779B2
(en)
*
|
2014-12-30 |
2017-01-24 |
Novira Therapeutics, Inc. |
Derivatives and methods of treating hepatitis B infections
|
|
WO2017091681A1
(en)
|
2015-11-24 |
2017-06-01 |
Aclaris Therapeutics, Inc. |
Selective kinase inhibitors
|
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
|
US11110108B2
(en)
|
2016-09-27 |
2021-09-07 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
|
|
US10759865B2
(en)
|
2017-08-22 |
2020-09-01 |
Eyal Levit |
Treatment of diabetes mellitus
|
|
WO2019046316A1
(en)
*
|
2017-08-28 |
2019-03-07 |
Acurastem Inc. |
PIKFYVE KINASE INHIBITORS
|
|
CN108586341B
(zh)
*
|
2018-05-25 |
2020-05-08 |
天津商业大学 |
酰胺类化合物和其药用盐及其制备方法和药物用途
|
|
AU2020242287A1
(en)
|
2019-03-21 |
2021-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
EP3947737A2
(en)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
WO2020212395A1
(en)
|
2019-04-16 |
2020-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
|
|
KR20220098759A
(ko)
|
2019-11-08 |
2022-07-12 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
키나제 억제제에 대해 내성을 획득한 암의 치료 방법
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
CN114605390B
(zh)
*
|
2020-12-04 |
2024-08-16 |
上海凌达生物医药有限公司 |
具有cdk激酶抑制活性的化合物、其药物组合物和用途
|
|
US12097261B2
(en)
|
2021-05-07 |
2024-09-24 |
Kymera Therapeutics, Inc. |
CDK2 degraders and uses thereof
|
|
US20250283174A1
(en)
|
2022-05-16 |
2025-09-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation
|